Home/Filings/4/0001209191-17-059624
4//SEC Filing

Crombez Eric 4

Accession 0001209191-17-059624

CIK 0001592288other

Filed

Nov 6, 7:00 PM ET

Accepted

Nov 7, 5:05 PM ET

Size

13.1 KB

Accession

0001209191-17-059624

Insider Transaction Report

Form 4
Period: 2017-11-07
Crombez Eric
Chief Medical Officer
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-11-07128,2920 total
    Exercise: $0.56Exp: 2024-12-16Common Stock (128,292 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-11-0780,3960 total
    Exercise: $4.09Exp: 2025-06-02Common Stock (80,396 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-11-0750,0000 total
    Exercise: $7.14Exp: 2026-01-31Common Stock (50,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-11-0750,0000 total
    Exercise: $1.90Exp: 2027-01-31Common Stock (50,000 underlying)
Footnotes (4)
  • [F1]This stock option, which vests over four years beginning December 1, 2014, at a rate of 25% on December 17, 2015, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.
  • [F2]This stock option, which vested 8,375 shares on December 1, 2015, and vests in 43 equal monthly installments thereafter, beginning December 3, 2015, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
  • [F3]This stock option, which vests in 48 equal monthly installments beginning January 27, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
  • [F4]This stock option, which vests in 48 equal monthly installments beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

Issuer

Dimension Therapeutics, Inc.

CIK 0001592288

Entity typeother

Related Parties

1
  • filerCIK 0001653052

Filing Metadata

Form type
4
Filed
Nov 6, 7:00 PM ET
Accepted
Nov 7, 5:05 PM ET
Size
13.1 KB